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OBJECTIVES The purpose of this multicenter study was to evaluate the safety and efficacy of a
radiofrequency (RF) catheter ablation system with internal saline irrigation.
BACKGROUND Catheter ablation of ventricular tachycardia (VT) associated with structural heart disease is
more difficult than ablation of idiopathic VT. The larger size of responsible reentrant circuits
contributes to the difficulty in achieving an adequate ablation lesion with conventional
techniques. Recently, cooling of the ablation electrode by saline irrigation has been shown to
increase RF lesion size.
METHODS The patient population included 146 patients who participated in the Cooled RF Ablation
System clinical trial and underwent an attempt at ablation of VT occurring in the presence of
structural heart disease. The duration of follow-up was 243 6 153 days.
RESULTS Catheter ablation was acutely successful, as defined by elimination of all mappable
VTs, in 106 patients (75%). In 59 patients (41%), no VT of any type was inducible
after ablation. Twelve patients (8%) experienced a major complication. After catheter
ablation, 66 patients (46%) developed one or more episodes of a sustained ventricular
arrhythmia.
CONCLUSIONS The results of this study demonstrate that catheter ablation of all mappable forms of sustained
VT can be performed with high initial success and a moderate incidence of major
complications (8%). (J Am Coll Cardiol 2000;35:1905–14) © 2000 by the American College
of Cardiology
Since the introduction of radiofrequency (RF) catheter
ablation into clinical use in the early 1990s, a number of
studies have evaluated its safety and effectiveness in the
treatment of ventricular tachycardia (VT) occurring either
in the presence or absence of structural heart disease (1–13).
Catheter ablation of idiopathic VT in the absence of
structural heart disease was rapidly determined to be a safe
and effective procedure and has gained widespread accep-
tance. In contrast, the safety and efficacy of catheter ablation
of VT associated with structural heart disease remainscon-
troversial. Previous studies have included relatively small
numbers of highly selected patients, often representing the
experience of a single institution. Variations in patient
selection, mapping and ablation methods and definitions of
success make evaluation of the risk/benefit ratio difficult.
There have been no multicenter or randomized trials.
It is generally recognized that ablation of VT associated
with structural heart disease is more difficult than ablation of
idiopathic VT. The relatively larger size of responsible
reentrant circuits, and the fact that they can be located deep
to the endocardium, often contribute to difficulty in achiev-
ing an adequate ablation lesion. Recently, cooling of the
ablation electrode by saline irrigation has been shown to
increase RF lesion size by 30% to 50% in animal models
(14,15). The purpose of this prospective multicenter study
was to evaluate the safety and efficacy of a RF catheter
ablation system with internal saline irrigation. The relation
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between acute procedural success, long-term success, and
clinical and electrophysiology (EP) variables were also
defined.
METHODS
Patient population. The patient population included 146
consecutive patients who participated in the Cooled RF
Ablation System (Cardiac Pathways, Sunnyvale, California)
clinical trial. The patients underwent an attempt at ablation
of VT occurring in the presence of structural heart disease at
1 of 18 institutions between September 1995 and December
1997. This trial was designed to study the effectiveness of an
ablation system incorporating internal saline irrigation.
Patients were initially recruited for the study if they fulfilled
the following criteria: 1) documented sustained monomor-
phic VT with two or more episodes in the two months
before enrollment; 2) spontaneous VT that was hemody-
namically stable; 3) VT due to ischemic heart disease; 4) an
implantable cardioverter defibrillator (ICD) device with
electrogram storage; and 5) failure of at least two antiar-
rhythmic agents. At the onset of the study, patients were
randomized 1:1 between ablation and continued antiar-
rhythmic therapy. As the study progressed, the enrollment
criteria were altered to facilitate enrollment, including
elimination of randomization and the requirement for an
ICD. A subgroup of patients was enrolled on a compas-
sionate use basis. Among the 146 patients included in this
report were four subgroups of patients. The first was
comprised of 63 patients who were randomized to catheter
ablation. The second was comprised of 17 patients who
were randomized to medical therapy and underwent cathe-
ter ablation after failure of medical therapy. The third was
comprised of 13 patients who received ablation under
compassionate use. The final subgroup was comprised of 53
patients who were enrolled in the study after the random-
ization arm of the study was discontinued. During the
course of the study, a total of 171 ablation procedures was
performed in these patients. Twenty-five patients under-
went two ablation procedures either because of failure of
an initial attempt (n 5 14) or after an arrhythmia recurrence
(n 5 11).
Patient evaluation, EP testing and catheter ablation.
Before the ablation procedure, each patient gave written
informed consent according to a protocol approved by the
Institutional Review Board. A history and physical exami-
nation, electrocardiogram (ECG), echocardiogram and
neurologic examination by a neurologist were also obtained.
Each patient underwent an EP test with the intent to
perform an ablation procedure using Cooled RF energy.
The inducibility of VT was assessed by programmed elec-
trical stimulation with one to three extra stimuli at two sites.
Ablation was performed with an investigational 7Fr quad-
ripolar electrode catheter with 2-5-2-mm interelectrode
spacing and a deflectable 4-mm electrode tip (Cardiac
Pathways Corporation Cooled RF catheter) (Fig. 1). Before
the ablation catheter was positioned in the left ventricle,
heparin was administered to achieve an activated clotting
time .250 s.
The four predefined criteria that were used to select target
sites included concealed entrainment, identification of an
isolated mid-diastolic potential, identification of the earliest
presystolic endocardial activation during VT and pace map-
ping. Investigators were instructed to deliver RF energy at
sites demonstrating concealed entrainment or a mid-
diastolic potential whenever possible. Pace mapping was
used to identify target sites only if alternative criteria were
not met. When an appropriate target site was identified, up
to 50 W of RF energy was delivered at 500 kHz (Cardiac
Pathways Model 8002 or 8004 RF Generator and inte-
grated Cooled Ablation Pump System; Cardiac Pathways).
Saline was infused through the catheter at 0.6 ml/s before
and during energy delivery. RF energy was then delivered
for 60 to 180 s in the power control mode. Power output
was automatically shut down if the impedance exceeded
250 V or if the electrode temperature exceeds 65°C. The
energy output was initially set at 25 W but was generally
increased incrementally during the RF application to
achieve an increase in the electrode temperature from
,31°C to between 40°C and 50°C.
The predetermined end point of the ablation procedures
was the elimination of all VTs that were associated with
sufficient hemodynamic stability to allow mapping to be
performed (mappable VTs). Thirty minutes after the suc-
cessful application of RF energy, programmed stimulation
was repeated. Before discharge, patients underwent a repeat
echocardiogram, as well as a second neurological examina-
tion. The cycle length, bundle branch block configuration
and axis of each VT was recorded. Ventricular tachycardias
that in the investigators judgement had occurred spontane-
ously were designated as a “clinical VT.”
Abbreviations and Acronyms
ECG 5 electrocardiogram
EF 5 ejection fraction
EP 5 electrophysiology
ICD 5 implantable cardioverter defibrillator
RF 5 radiofrequency
VT 5 ventricular tachycardia Figure 1. Schematic drawing showing the cooled RF ablation
catheter. Cooling is achieved by circulating saline through the
ablation electrode.
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Clinical follow-up. Each patient was evaluated 1, 3, 6, 9,
12, and 24 months after ablation. According to the study
protocol, patients were to be continued on the type of
antiarrhythmic therapy they had received before ablation for
at least the first three months after hospital discharge. The
mean duration of clinical follow-up was 243 6 153 days.
Outcomes. There were three end points of the study: acute
success, long-term success and safety. Acute success was
defined as absence of inducible, mappable VT at the end of
the ablation procedure. This was a strict criteria; if three
mappable VTs were identified and only two were ablated,
the procedure was classified as a failure. Long-term success
was defined as the absence of any spontaneous sustained VT
during follow-up. By this definition, failures included pa-
tients with arrhythmias that had not been targeted for
ablation, including polymorphic VT and unmappable rapid
VT. Data on patients who experienced neither recurrence
nor death were censored at the last follow-up. Safety was
assessed in terms of the procedure-related adverse event
rate. Complications were classified as major or minor. Major
complications were defined as those that resulted in perma-
nent injury or death, required an intervention for treatment
or prolonged the duration of hospitalization. All other
adverse events were classified as minor.
During the course of the trial, several studies demon-
strated the efficacy of ICDs for preventing sudden death.
Therapy that achieved a reduction in spontaneous episodes
of arrhythmia, reducing the frequency of ICD shocks,
became recognized as beneficial (9). Therefore, an addi-
tional outcome measure, clinical success, defined as a .75%
reduction in spontaneous VT episodes during follow-up as
compared with the two months before ablation, was also
assessed.
Data analysis and statistical methods. The covariates of
interest in the study fell into three broad groups. The first
group of covariates was related to demographic and baseline
characteristics and included patient’s age and gender, study
subgroup to which patient belonged, volume of procedures
performed at the ablation center, cause of VT and ejection
fraction (EF). The second group of covariates was related to
arrhythmia history and included whether the patient had
ever undergone a previous ablation, number of VT episodes
in the two months before the ablation procedure, whether
amiodarone therapy failed, the number of clinical VTs
.300 ms, whether a clinical VT was induced, whether the
patient had only one slow VT .300 ms and whether the
patient was implanted with an ICD at discharge postabla-
tion. The third group of covariates was related to preabla-
tion diagnostic EP assessments and included such measures
as number of inducible VTs and number of VTs with a cycle
length ,300 ms.
Patients for whom the catheter ablation procedure was an
acute and/or long-term success were compared with those
for whom the procedure was a failure, as defined above, with
respect to these characteristics. All significance tests were
two-sided, with alpha 5 0.05 level of confidence. Signifi-
cant differences in proportions of success by patient group
were assessed by examining the chi-square statistics from
two-by-two tables. Covariates that were significantly asso-
ciated with procedure success in two-by-two tables were
then examined in a logistic regression framework. An
unadjusted odds ratio corresponding to each covariate was
estimated first from a univariable regression. Thereafter, an
adjusted odds ratio for each covariate was estimated after
controlling for baseline and demographic characteristics
deemed likely to confound any analysis of the association
between the covariate and procedure success. The signifi-
cance of the regression parameter corresponding to each
covariate was assessed by both the -2-log-likelihood (-2LL)
statistic, a likelihood ratio test to determine the improve-
ment in model goodness-of-fit with the addition of the
covariate to the baseline model, as well as the Wald statistic,
a test to determine the significance of each regression
parameter compared with its expected standard normal
distribution.
Long-term success (i.e., time to VT recurrence and time
to death) was also examined in a survival analysis frame-
work. Time-to-event survival curves were graphed for dif-
ferent patient subgroups using the Kaplan-Meier estimation
technique. Thereafter, Cox proportional hazards models
were fitted to assess which factors were associated with risk
of recurrence and risk of death. In a fashion similar to the
logistic regression analyses above, characteristics that ap-
peared to distinguish survivorship curves were then assessed
in a proportional hazards regression framework. An unad-
justed hazards ratio corresponding to each covariate was
estimated first from a univariable regression. Thereafter, an
adjusted hazards ratio for each covariate was estimated after
controlling for baseline and demographic characteristics
deemed likely to confound any analysis of the association
between the covariate and long-term success. The signifi-
cance of the regression parameter corresponding to each
covariate was assessed by both the -2LL statistic as well as
the Wald statistic.
RESULTS
Patient characteristics. The clinical characteristics and
electrophysiologic features of the 146 patients included in
this study are shown in Table 1. Structural heart disease was
present in all patients, with ischemic heart disease present in
119 (82%). The mean left ventricular EF was 31 6 13%.
One hundred seven patients (73%) had an EF # 35%. All
patients in this study had failed prior antiarrhythmic therapy
with 2.5 6 1.5 drugs, including amiodarone therapy in 58
patients (40%). The number of VT episodes in the preced-
ing two months was 25 6 31. Fifty-eight patients (40%)
had inducible rapid VTs with a cycle length shorter than
300 ms. One hundred six patients had an ICD implanted
before their ablation procedure. An additional nine patients
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received an ICD before hospital discharge. Thus, 119
patients (79%) had an ICD implanted.
Acute success of catheter ablation. During EP testing,
3 6 2 VT morphologies were induced, including the
patients’ clinical VT in 126 patients (89%). The number of
RF applications was 12 6 10. The maximum power
delivered was 35 6 9 W, with a mean duration of RF
applications of 63 6 41 s. One patient received no RF
applications because an acceptable site for ablation was not
identified. Two ablation sessions were required in 14 pa-
tients. The duration of the procedure was 288 6 160 min,
with 56 6 42 min of fluoroscopy.
Based on an intention-to-treat analysis, catheter ablation
was acutely successful, as defined prospectively by elimina-
tion of all mappable VTs in 106 patients (75%). Acute
efficacy was not determined in three patients. In 59 patients
(41%), no VT of any type, mappable or unmappable, was
inducible after the ablation procedure. The results of uni-
variable analysis revealed that the likelihood of acute suc-
cess, defined as abolition of mappable VTs, was not influ-
enced by any of the variables that we examined including
age, gender, VT cause, EF, prior ablation attempt, failure of
amiodarone, the number of induced VTs or the number of
clinical episodes of VT. The only two variables that were
associated with successful ablation of all induced VTs were
prior failure of amiodarone and the number of induced VTs
with a cycle length .300 ms. Ablation of all VTs was less
likely in patients who had previously failed amiodarone or
who had multiple (greater than two morphologies) or
relatively slow (cycle length .300 ms) VTs. In multivariable
analysis after controlling for age, gender and EF, the results
remained essentially unchanged (Table 2). For success
defined as ablation of mappable VTs, no variable or com-
bination of variable in multivariate analysis was predictive.
No difference was observed in the power of RF applications
(36 6 8 vs. 36 6 8 W, p 5 0.64), the duration of RF
applications (63 6 43 vs. 55 6 27 s, p 5 0.16) or the
electrode temperature (466 12 vs. 47 6 12°C, p 5 0.58)
between patients with and without acute success. The
number of delivered RF applications was greater in patients
in whom catheter ablation failed (16 6 14 vs. 12 6 8, p ,
0.01).
Complications. A procedure-related major complication
occurred during or after the ablation procedure in 12
patients (8%) and a minor complication developed in 9
patients (6%). Four of the major complications led to a
patient death (2.7%). The type and distribution of compli-
cations are shown in Table 3. The most significant compli-
cations were four strokes or transient ischemic attacks, four
episodes of pericardial tamponade, inadvertent complete
heart block in two patients, one myocardial infarction and
aortic valve injury in one patient. Among the four patients
Table 1. Patient Characteristics
Demographic n (%)
Age (mean years, SD) 65, 12.6
30–65 67 (46%)
.65 79 (54%)
Gender (% male) 134 (92%)
Ischemic heart disease 119 (82%)
Ejection fraction (mean, SD) 31, 13
0–20 41 (28%)
21–35 66 (45%)
361 39 (27%)
Group
Crossover 17 (12%)
Randomized to ablation 63 (43%)
Compassionate use 15 (10%)
Nonrandomized 51 (35%)
Center (n, % patients enrolled)
High 60 (41%)
Medium 41 (28%)
Low 45 (31%)
Arrhythmia history
Prior ablation 32 (22%)
Failed amiodarone 58 (40%)
Number prior VT episodes
0 to 2 27 (19%)
3 to 8 67 (46%)
10 to 99 42 (29%)
100 1 10 (7%)
Only 1 VT, CL .300 ms 33 (23%)
Clinical VT induced 126 (89)
Number of VTs CL .300
0 to 1 55 (39%)
$2 87 (61%)
ICD at entry 106 (71%)
ICD at discharge 115 (79%)
Number failed AA drugs (mean, SD) 2.5, 1.5
EP findings
Induced VTs (mean, SD) 3 (2.1)
VT CL #300 0.7 6 0.6
VTs .300 2.4, 1.9
Noninducible 1 (0.7%)
With 1 VT induced 37 (25%)
With 2 VTs induced 35 (25%)
With .2 VTs induced 70 (49%)
ICD 5 implantable cardioverter defibrillator; VT 5 ventricular tachycardia.
Table 2. Multivariable Model for Ablation of All VTs
Predictor
Adjusted
OR
p
Value
Age (651 years) 0.69 0.34
Gender (male) 0.61 0.5
EF (,35%) 0.72 0.42
Failed amiodarone 0.44 0.03
$2 inducible VTs, CL .300 0.46 0.04
The adjusted odds ratio represents the increase (.1.0), or decrease (,1.0) in the odds
of having acute success associated with the presence of a specific variable, assuming
that all other variables in the model are equal. The odds of success are defined as the
probability of success/12 probability of success.
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with pericardial tamponade, only one appeared to be tem-
porally related to delivery of RF energy. This patient had
right ventricular dysplasia. Ablation at a site located on the
free wall aspect of the right ventricular outflow tract was
associated with pericardial tamponade, which required sur-
gical repair because a pericardiocentesis was precluded due
to an ICD patch. A “pop” was not reported in association
with this RF application. Paired echocardiographic analysis
revealed no change in ventricular function before and after
ablation (31 6 13 vs. 30 6 13, p . 0.1).
There were four procedure-related deaths. The first
patient was a 63-year-old man with ischemic heart disease.
Thirty minutes after successful ablation of VT, the patient
became hypotensive. Catheterization revealed a 99% occlu-
sion of the left main coronary artery most consistent with a
coronary embolus. Despite an angioplasty with initial clin-
ical improvement, the patient’s condition deteriorated, and
he died of cardiogenic shock. Upon review of ACT levels, it
was evident that despite receiving heparin, the ACT re-
mained subtherapeutic. The second patient was a 72-year-
old man with a severe ischemic cardiomyopathy who devel-
oped acute pericardial tamponade. A transeptal approach
was used to advance the ablation catheter into the left
ventricle. After delivery of three RF energy applications, the
patient became hypotensive. A pericardiocentesis was per-
formed followed by surgical repair of a perforation in the left
atrial appendage. The patient initially recovered but devel-
oped pneumonia and progressive heart failure resulting in
death one week later. The third patient was a 49-year-old
man with an ischemic cardiomyopathy. The patient under-
went a successful ablation, but suffered a cerebrovascular
accident that progressed to herniation and death. The
fourth procedure-related death was in a 74-year-old man
with an ischemic cardiomyopathy (EF 5 15%), moderate
mitral regurgitation and mild aortic insufficiency. An echo-
cardiogram obtained after two ablation procedures 48 h
apart demonstrated increased aortic regurgitation. The pa-
tient subsequently underwent a previously planned coronary
artery bypass graft; aortic valve replacement and mitral
annuloplasty were also performed. At surgery, the aortic
valve was noted to be friable with a tear attributed to
catheter injury. The patient died from cardiogenic shock on
the day after surgery.
Arrhythmia recurrence. Consistent with the study proto-
col, the majority of patients in this study were discharged on
the same antiarrhythmic therapy they were receiving before
ablation. Antiarrhythmic drug therapy at the time of hos-
pital discharge consisted of amiodarone in 42% of patients,
sotolol in 12% of patients and a type 1 antiarrhythmic agent
in 12% of patients. Although it was recommended that
patients continue on the antiarrhythmic therapy they re-
ceived before catheter ablation for at least the first three
months after hospital discharge, the use of antiarrhythmic
therapy decreased with time. At three months of follow-up,
33% of patients were treated with amiodarone, 11% were
treated with a class 1 antiarrhythmic agent and 12% were
treated with sotolol. At the time of last follow-up, the use of
these three types of antiarrhythmic agents had decreased to
30%, 5% and 10%, respectively.
After catheter ablation, 66 (46%) of the 146 patients
developed one or more episodes of a sustained ventricular
arrhythmia during 243 6 153 days of follow-up. The
median time to VT recurrence was 24 days (range 1 to 309
Figure 2. Kaplan-Meier curve showing freedom from arrhythmia
recurrence among patients who underwent ablation of VT.
Table 3. Procedure-related Complications
Complication Type
No. of
Patients
No. of
Deaths
Major complications
Stroke/TIA 4 (2.7%) 1
Complete AV block 2 (1.4%) 0
Tamponade 4 (2.7%) 1
Valve injury 1 (0.7%) 1
Myocardial infarction 1 (0.7%) 1
Femoral artery laceration 1 (0.7%) 0
No. of patients with a major
complication
12 (8%) 4 (2.7%)
Other complications
Aortic dissection (distal) 1 (0.7%)
Defibrillation skin burn 1 (0.7%)
Anxiety and stress 1 (0.7%)
Peroneal nerve palsy (transient) 1 (0.7%)
Loss of pulses in extremity (transient) 1 (0.7%)
Pseudoaneurysm (no treatment
required)
1 (0.7%)
Transient left leg numbness 1 (0.7%)
Slurred speech due to sedation 1 (0.7%)
Visual blurring (transient) 1 (0.7%)
Other AV block* 0 (0%)
No. of patients with a minor
complication
9 (6%)
*Transient AV block, 1° or 2° AV block.
AV 5 arterio-ventricular.
1909JACC Vol. 35, No. 7, 2000 Calkins et al.
June 2000:1905–14 Catheter Ablation of Ventricular Tachycardia
days). The one-year recurrence rate by the Kaplan-Meier
method was 56% (Fig. 2). In univariable analysis, three
variables were predictive of absence of recurrence of a
sustained ventricular arrhythmia during follow-up: 1) age
.65 years; 2) at least three episodes of VT in the two
months before ablation and 3) the absence of an ICD at
hospital discharge (p , 0.05). Interestingly, acute success
was not predictive of clinical success. Ventricular tachycar-
dia recurred in 44% of patients who had no inducible VT at
the end of the procedure and in 46% of patients who had
any VT inducible at the end of the procedure.
Table 4 shows the results of multivariate logistic regres-
sion analysis. The three variables identified as jointly pre-
dictive of freedom from VT recurrence were: 1) age, 2) at
least three episodes of VT in the two months before ablation
and 3) the presence of an ICD at discharge. A Cox
proportional hazards multivariate regression analysis iden-
tified the number of VT episodes in the two months before
ablation, and the presence of an ICD at hospital discharge
to be jointly predictive of the time to arrhythmia recurrence
(Table 5, Figs. 2 and 3).
A measure of clinical success ($75% reduction in the VT
frequency in the two months after ablation) was assessed
among the 122 patients who were followed for at least two
months. Clinical success was observed in 99 patients (81%)
of patients. Only the presence of an inducible VT identified
as a clinical VT was identified as a predictor of clinical
success (Tables 5 and 6). A trend was also observed
suggesting a greater likelihood of clinical success among
those who had not previously failed treatment with amio-
darone. The results of programmed stimulation at the end
of the procedure (acute success or failure) were not predic-
tive of clinical success.
Long-term survival. Twenty-six patients died either in the
periprocedural period (n 5 4, see above) or during follow-
up. Of the 22 nonprocedure related deaths, 2 were attrib-
uted to noncardiac causes (e.g., cancer, COPD), 16 were
classified as cardiac nonarrhythmic (e.g., pump failure) and
4 were presumed due to a ventricular arrhythmia. Total survival
was estimated by the Kaplan-Meier method. Overall, 75%
of patients were alive at one year of follow-up (Fig. 4).
When separate logistic regression models were used to
assess the odds of survival during follow-up, the only two
variables that were identified were younger age and the
presence of fewer than two types of inducible sustained VT
Figure 3. Kaplan-Meier curve showing freedom from arrhythmia
recurrence among patients who underwent catheter ablation of VT
subclassified by whether the patient was discharged with or
without an ICD.
Table 4. Multivariate Logistic Regression Model: Recurrence
and Survival
Predictor
Adjusted Odds
Ratio
p
Value
Long–term survival
Age (651 years) 0.31 0.02
Gender (male) 3.9 0.06
EF (,35) 0.41 0.16
$2 VTs CL .300 0.23 0.02
Clinical success
Age (651 years) 1.02 0.96
Gender (male) 1.21 0.83
EF (,35%) 1.24 0.71
Failed Amiodarone (yes) 0.43 0.09
Clinical VT induced (yes) 4.57 0.03
No VT recurrence
Age (651 years) 0.41 0.02
Gender (male) 1.37 0.67
EF (,35%) 2.32 0.06
VT episodes post (31) 0.23 0.02
ICD at discharge (yes) 0.08 0.002
CL 5 cycle length (ms); EF 5 ejection fraction; ICD 5 implantable cardioverter
defibrillator; VT 5 ventricular tachycardia.
Table 5. Multivariate Cox Proportional Hazards Models for
Prediction of Time to Recurrence
Predictor
Adjusted Odds
Ratio
p
Value
Age (651 years) 1.67 0.06
Gender (male) 1.18 0.74
Ejection fraction (.35%) 1.38 0.24
Prior VT episodes (.2) 2.37 0.05
ICD at discharge 7.14 0.001
Abbreviations are defined in Table 4 legend.
Table 6. Multivariate Cox Proportional Hazards Models for
Prediction of Time to Death
Predictor
Adjusted
Odds Ratio
p
Value
Age (651 years) 2.37 0.04
Gender (male) 0.44 0.14
VT cause (ischemic) 0.46 0.10
Ejection fraction (.36%) 0.35 0.06
Number of VTs CL .300 3.52 0.02
Abbreviations are defined in Table 4 legend.
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with a cycle length .300 ms before ablation. Table 4 shows
the results of multivariate logistic regression analysis for
prediction of survival. Patient age and the presence of less
than two types of inducible sustained VT with a cycle length
.300 ms before ablation were identified. Figure 4 shows a
Kaplan-Meier curve showing the time to death. A Cox
proportional hazards multivariate regression analysis also
identified age and multiple morphologies of relatively slow
sustained VT (cycle length .300 ms) as predictive of death.
A trend was also shown suggesting a greater mortality
among those with an EF #35% (Table 6).
DISCUSSION
Main findings. The present study is the first prospective
multicenter trial to evaluate the safety and efficacy of
catheter ablation of VT and to report the use of an internally
cooled RF ablation system in humans. The results of this
study demonstrate that catheter ablation of all mappable
forms of sustained VT, in patients with very frequent
episodes of VT and severely impaired ventricular function,
can be performed with high immediate success (75%), and
a moderate incidence of major complications (8%). Fifty-
four percent of patients were rendered free of VT during
follow-up. As appropriate for the initial evaluation of a new
technology, this study enrolled only patients with arrhyth-
mias that were refractory to antiarrhythmic therapy. The
definitions of success were strict. The presence of any
inducible VT that was mappable was considered a proce-
dural failure, even if other morphologies of VT were
successfully abolished. During follow-up, recurrence of any
sustained VT was counted as a recurrence, even if the
arrhythmia was not one that had been targeted for ablation.
Thus, a patient undergoing catheter ablation of recurrent
slow VT who had an ICD discharge due to polymorphic
VT during follow-up was classified as having a recurrence.
This definition was chosen as to eliminate any possibility of
bias on the part of the investigators given that the classifi-
cation of VTs as “clinical” versus “nonclinical” are highly
subjective.
Cooled RF ablation. Ventricular tachycardia associated
with structural heart disease is often due to reentry through
regions of myocardial scar. The relatively larger size of
reentry circuits and the fact that they can be located deep to
the endocardium is felt to be responsible, at least in part, for
the greater difficulty and lower efficacy of catheter ablation
as compared with ablation of supraventricular tachycardias
and idiopathic VT (16,17). Surgical ablation of VT often
requires removal or laser coagulation of 2 to .40 cm2 of
tissue (18). With conventional RF ablation, application of
RF energy is limited when excessive heat transfer to the
ablation electrode results in formation of an insulating
coagulum on the electrode surface, preventing further en-
ergy delivery. Individual RF lesions are generally less than
1 cm in diameter. Cooling of the ablation electrode by saline
irrigation has been shown to allow production of larger RF
lesions in animal models, presumably by allowing greater
energy delivery before coagulum formation (14,15,19). This
is the first large-scale evaluation of this technology in
humans.
The potential for greater lesion size is expected to
increase the likelihood of successful ablation. This study did
not compare cooled RF ablation with standard RF ablation;
therefore, the relative efficacy remains unclear. In several
recent studies of standard RF ablation, the VT recurrences
during follow-up have ranged from 16% to 45% (6,8–11).
These trials often selected patients for one “clinical” mor-
phology of VT (6,11). In some studies, only recurrences of
the VT that was targeted for ablation were considered
arrhythmia recurrences. Rothman et al. (8) recently reported
their experience with catheter ablation of VT in 35 patients
with ischemic heart disease and VT that was sufficiently
stable to allow adequate mapping to be performed. Catheter
ablation was successful in eliminating all VTs in 11 patients
and was successful in eliminating the “clinical VT” in 31
patients. Thus, based on an intention-to-treat analysis as
was used in the present study, 75% of patients had their
clinical VT successfully ablated and 26% of patients were
rendered completely noninducible. The recurrence rate at
24 months was 34%. In a similar series of 52 patients,
ablation of all inducible VTs was achieved in 40% of
patients; the recurrence rate at three years was 33% (10).
Differences in patient selection make comparisons difficult.
The potential for greater lesion size may also introduce
the potential for increasing complications related to myo-
cardial damage. The 8% incidence of major complications in
this study is more than twofold higher than the 3%
incidence of major complications reported during ablation
of supraventricular arrhythmias (20). The data reported in
the Multicenter European Radiofrequency Survey
(MERFS) and the NASPE survey may provide a better
benchmark with which to compare the complication rate
Figure 4. Kaplan-Meier curve showing patient survival after ab-
lation of VT.
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reported in this trial (21,22). Among the 320 patients who
underwent catheter ablation of VT in the MERFS registry,
the major complication rate was 7.5%, which is remarkably
similar to the 8% complication major rate reported in the
present study. However, the incidence of certain major
complications was greater in the present study than was
reported based on the MERFS data (cerebrovascular event,
2.7% vs. 1.3%; cardiac tamponade, 2.7% vs. 0.3%; and
death, 2.7% vs. 0.3%). Scheinman (22) reported a major
complication rate of 2.3% among the 844 patients under-
going VT ablation enrolled in the NASPE survey, including
six instances of pericardial tamponade and three systemic
emboli. These differences in complication rates most likely
large differences in study design. In addition, both the
MERFS registry and the NASPE survey enrolled patients
who were undergoing catheter ablation of either idiopathic
or nonidiopathic VT, whereas the present study enrolled
only patients undergoing catheter ablation of VT in the
setting of structural heart disease. Therefore, the complica-
tion rates are not directly comparable. In other recent series
of VT ablation, the incidence of complications has ranged
from 5% to 12% (6,8–11). During cooled RF ablation, the
potential exists for achieving temperatures of 100°C deep to
the endocardium. Studies in in vitro and in vivo models have
shown that steam formation can cause rupture of overlying
myocardial tissue either into the myocardial cavity or out-
ward to the pericardium (14,15,19). It is reassuring, there-
fore, that in the present series only one patient, who had
right ventricular dysplasia and was undergoing ablation of
the free wall of the outflow tract, developed pericardial
tamponade during an application of RF energy. It is also
reassuring to note that no change in ventricular function was
observed after catheter ablation. The 11% incidence of
death due to heart failure during follow-up is also similar to
that in other series of patients with ventricular arrhythmias
and does not suggest excessive myocardial damage (10,11).
Factors affecting ablation success and recurrence. Suc-
cessful ablation of VT requires both accurate mapping of the
VT circuit as well as creation of a lesion of sufficient size.
The primary end point of this study, which was prospec-
tively defined as successful ablation of all forms of mappable
VT, was accomplished in 75% of patients. No clinical
variables were predictive of this definition of acute success,
and similar acute success rates were achieved in patients
with ischemic and nonischemic heart disease. The inability
of any variable to predict acute success may reflect the
importance of the skill of the operator, which was not
included in this analysis. The absence of any difference in
delivered power and electrode temperature during successful
versus failed procedures likely reflects the critical importance
of mapping to the overall ablation success. A secondary
acute end point of this study was successful ablation of all
VTs. This was accomplished less frequently, in 41% of
patients, because faster VTs that are not mappable often
coexist with slow VTs in these patients. The two variables,
which were predictive of an inability to ablate VTs, were
prior amiodarone failure and the presence of multiple
relatively slow VTs (cycle length .300 ms). Forty-six
percent of patients experienced a recurrence after their
ablation procedure. This apparently high recurrence rate can
be understood, in part, based on the fact that 40% of
patients had rapid VTs induced before the ablation proce-
dure that were hemodynamically unstable and were there-
fore not targeted. It is also important to note that a
development of “recurrence” was defined as the develop-
ment of any type of sustained VT during follow-up.
Surprisingly, acute success was not predictive of arrhythmia
recurrence during follow-up. Acute success was defined by
programmed stimulation at the end of the ablation proce-
dure. Over the ensuing days to weeks, there is further
healing of ablation lesions, with resolution of some of the
initial injury in some cases and, occasionally, expansion in
others, accounting for the 8% recurrence rate after successful
ablation of an accessory pathway (20). It appears that the
likelihood of arrhythmia recurrence after VT ablation is
higher, possibly related to resolution of some of the acute
injury. This problem may be magnified when a relatively
large ablation lesion is required to interrupt a reentry circuit.
Although we attempted to maintain a stable antiarrhythmic
regimen after ablation, changes are inevitable given the
frequency of side effects of these drugs and that many
patients had multiple trials of drug therapy before ablation.
The two variables that were predictive of arrhythmia recur-
rence were the number of VT episodes before ablation and
the presence of an ICD at discharge. Whereas only 10% of
those patients discharged without an ICD developed a
recurrence, more than 50% of those patients discharged
with an ICD had a recurrent episode. Patients with a
persistently inducible VT and worse ventricular function
may have been more likely to receive an ICD, even if
ablation of all mappable was achieved.
Survival. The one-year survival rate after catheter ablation
was 75%. The two factors identified by multivariate analysis
as independent predictors of increased risk of death included
age over 65 years, and multiple morphologies of slow
inducible sustained VT. There was also a strong trend
showing a relationship between worse survival and impaired
ventricular function (p 5 0.06). It is not surprising that
increased age and greater impairment of ventricular function
predict mortality. However, the predictive value of multiple
morphologies of slow VT has not previously been reported.
Given that nearly 80% of patients in this series were
discharged with ICDs and that 73% of deaths were related
to heart failure, it seems likely that multiple VTs may be
associated with a larger scar, worse ventricular function and
greater risk of death from pump failure.
Comparison with prior reports. A number of studies
have been published that have reported the results of
catheter ablation of nonidiopathic VT. The majority of
these studies have been confined to patients with isch-
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emic heart disease (5–12). Rothman et al. (8) recently
reported their experience with catheter ablation of VT in
35 of 42 patients with ischemic heart disease who were
determined to have VT that was sufficiently stable to
allow adequate mapping to be performed. Catheter abla-
tion was successful in eliminating all VTs in 11 patients
and was successful in eliminating the “clinical VT” in 31
patients. Thus, based on an intention-to-treat analysis as
was used in the present study, 74% of patients had their
clinical VT successfully ablated and 26% of patients were
rendered completely noninducible. The recurrence rate at
24 months was 34%. The largest series of patients
undergoing RF ablation of nonidiopathic VT published
to date, by Gonska et al. (11), reported an acute success
rate of 74% among 72 patients with one configuration of
monomorphic VT in the setting of ischemic heart dis-
ease. Similar results have been reported by others in
clinical series involving 21 or fewer patients (5–7).
Scheinman reported a 66% success rate among the 257
patients undergoing ablation of VT in the setting of
ischemic heart disease who were enrolled in the NASPE
survey (22). There is considerably less experience with
catheter ablation of VT in the setting of nonischemic
heart disease. The only series published to data, by
Kottkamp et al. (13), involved eight patients with recur-
rent VT in the setting of a dilated cardiomyopathy. Six of
nine targeted VTs were successfully ablated and three of
nine patients were rendered noninducible. During follow
up, one patient died suddenly, five developed recurrent
VT and two patients remained free of recurrent arrhyth-
mias. The success rate for ablation of VT associated with
cardiomyopathy in the NASPE survey was 68% (22).
It is difficult to directly compare the results of the
present study with the findings of these prior reports for
a number of reasons. First, this study is the first prospec-
tive multicenter trial of catheter ablation of nonidiopathic
VT that has ever been performed. Second, this study
involved a larger number of patients and enrolled patients
with and without ischemic heart disease. Third, the
definitions of acute success and long-term success have
varied between trials. And finally, catheter ablation in the
clinical trial was performed with an ablation system that
incorporated internal cooling whereas prior studies have
employed conventional RF ablation techniques. This
study was not designed to compare the safety and efficacy
of catheter ablation of nonidiopathic VT using cooled RF
energy versus conventional RF ablation techniques. Be-
cause of these significant differences in study design, it is
impossible to directly compare the results of this trial
with prior reports. Nonetheless, it is notable that the
acute success rate reported in this trial is not significantly
different from prior reports and that the recurrence and
complication rates are somewhat greater. Although we
feel that these differences reflect the prospective multi-
center design of this trial and the prospectively defined
definitions of acute and long-term success used in this
trial, it is possible that these findings reflect the absence
of an intrinsic advantage of cooled RF ablation as
compared with conventional RF ablation techniques.
Hopefully, future trials will be performed to directly
compare these two energy sources.
Study limitations. There are several limitations that
should be considered when interpreting the results of this
study. This study was a prospective multicenter clinical trial
that evaluated the safety and efficacy of catheter ablation of
nonidiopathic VT using the Cooled RF Ablation system.
However, it should be recognized that the number of
patients enrolled at participating institutions ranged from 3
to 32. Therefore, it is possible that the relatively low efficacy
and high incidence of complications may in part be attrib-
utable to an unequal distribution of mapping/ablation skills
at participating centers. Although additional important
information could have been learned if patients were ran-
domized to undergo catheter ablation of VT with either the
Cooled RF Ablation System or standard RF ablation, this
study design was not used. A second limitation of this study
was that the type of structural heart disease present in study
patients was classified by the investigator as to whether they
did or did not have ischemic heart disease. The types of
nonischemic cardiomyopathies were not broken down fur-
ther. Although this represents a limitation of this article, the
great majority of patients in this study had ischemic heart
disease (82%). It is unlikely that the major findings of this
study would have been significantly altered by a further
subclassification of the 18% of patients with nonischemic
heart disease according to the types of nonischemic cardio-
myopathy that were present.
Clinical implications. Management of VT associated with
structural heart disease is often difficult. Recurrences are
frequent despite antiarrhythmic therapy. Implantable car-
dioverter defibrillators offer excellent protection from sud-
den death, but do not prevent episodes of arrhythmia.
Management of frequent VT recurrences has become an
important problem in caring for patients with ICDs. This
study further defines the efficacy and risks of catheter
ablation for patients with recurrent episodes of VT. Preven-
tion of further spontaneous episodes of VT was achieved in
54% of patients. This efficacy must be balanced against the
risk of procedure complications including stroke (2.7%) and
death (2.7%).
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